BACKGROUND: Human platelet activation and aggregation is a complex process. To date, many therapies have been developed targeting proteins that mediate this process to prevent unwanted activation. However, the current standard of care for acute coronary syndromes still has limitations, including bleeding risk. OBJECTIVE: To evaluate the protease-activated receptor 4 (PAR4) anionic cluster as a viable antiplatelet target by using a polyclonal antibody (CAN12). METHODS: We used western blotting, aggregation and secretion ex vivo to evaluate the ability of CAN12 to interact with PAR4 and inhibit platelet activation. The effects of CAN12 in vivo were evaluated with the Rose Bengal arterial thrombosis model and two models of hemostasis. RESULTS: CAN12 was able to interact with human PAR4 and delay PAR4 cleavage. In addition, CAN12 inhibited thrombin-induced human platelet aggregation and secretion in a dose-dependent manner. The specificity of CAN12 was agonist-dependent. In vivo, we determined that CAN12 was able to inhibit arterial thrombosis, and, using two independent methods, we found that CAN12 did not influence hemostasis. CONCLUSION: Targeting the extracellular anionic cluster on PAR4 is a viable novel strategy as an antiplatelet therapy.
BACKGROUND:Human platelet activation and aggregation is a complex process. To date, many therapies have been developed targeting proteins that mediate this process to prevent unwanted activation. However, the current standard of care for acute coronary syndromes still has limitations, including bleeding risk. OBJECTIVE: To evaluate the protease-activated receptor 4 (PAR4) anionic cluster as a viable antiplatelet target by using a polyclonal antibody (CAN12). METHODS: We used western blotting, aggregation and secretion ex vivo to evaluate the ability of CAN12 to interact with PAR4 and inhibit platelet activation. The effects of CAN12 in vivo were evaluated with the Rose Bengal arterial thrombosis model and two models of hemostasis. RESULTS: CAN12 was able to interact with humanPAR4 and delay PAR4 cleavage. In addition, CAN12 inhibited thrombin-induced humanplatelet aggregation and secretion in a dose-dependent manner. The specificity of CAN12 was agonist-dependent. In vivo, we determined that CAN12 was able to inhibit arterial thrombosis, and, using two independent methods, we found that CAN12 did not influence hemostasis. CONCLUSION: Targeting the extracellular anionic cluster on PAR4 is a viable novel strategy as an antiplatelet therapy.
Authors: Michael Holinstat; Bryan Voss; Matthew L Bilodeau; Joseph N McLaughlin; John Cleator; Heidi E Hamm Journal: J Biol Chem Date: 2006-07-12 Impact factor: 5.157
Authors: J J J VAN Giezen; L Nilsson; P Berntsson; B-M Wissing; F Giordanetto; W Tomlinson; P J Greasley Journal: J Thromb Haemost Date: 2009-06-23 Impact factor: 5.824
Authors: Alaji Bah; Zhiwei Chen; Leslie A Bush-Pelc; F Scott Mathews; Enrico Di Cera Journal: Proc Natl Acad Sci U S A Date: 2007-07-02 Impact factor: 11.205
Authors: Shauna L French; Claudia Thalmann; Paul F Bray; Lynn E Macdonald; Andrew J Murphy; Mark W Sleeman; Justin R Hamilton Journal: Blood Adv Date: 2018-06-12
Authors: Annachiara Mitrugno; Samuel Tassi Yunga; Joanna L Sylman; Jevgenia Zilberman-Rudenko; Toshiaki Shirai; Jessica F Hebert; Robert Kayton; Ying Zhang; Xiaolin Nan; Joseph J Shatzel; Sadik Esener; Matthew T Duvernay; Heidi E Hamm; András Gruber; Craig D Williams; Yumie Takata; Randall Armstrong; Terry K Morgan; Owen J T McCarty Journal: Am J Physiol Cell Physiol Date: 2018-11-21 Impact factor: 4.249